8-K filing — Spero Therapeutics, Inc. (SPRO)
Filed: 2026-08-28 AccNo: 0001193125-26-374788 Size: 148 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355)Innovent will receive an upfront payment, and is
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
-SEC Filing
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoY
Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.